US5229526A - Metal alkoxides - Google Patents

Metal alkoxides Download PDF

Info

Publication number
US5229526A
US5229526A US07/862,778 US86277892A US5229526A US 5229526 A US5229526 A US 5229526A US 86277892 A US86277892 A US 86277892A US 5229526 A US5229526 A US 5229526A
Authority
US
United States
Prior art keywords
solution
taxol
mixture
triethylsilyl
thf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US07/862,778
Other languages
English (en)
Inventor
Robert A. Holton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Florida State University
Original Assignee
Florida State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
US case filed in New Jersey District Court litigation Critical https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/3%3A16-cv-02259 Source: District Court Jurisdiction: New Jersey District Court "Unified Patents Litigation Data" by Unified Patents is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Florida State University filed Critical Florida State University
Priority to US07/862,778 priority Critical patent/US5229526A/en
Assigned to FLORIDA STATE UNIVERSITY reassignment FLORIDA STATE UNIVERSITY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: HOLTON, ROBERT A.
Priority to IL103192A priority patent/IL103192A/xx
Priority to PH44959A priority patent/PH30213A/en
Priority to PT100884A priority patent/PT100884B/pt
Priority to MYPI92001683A priority patent/MY128481A/en
Priority to AU26888/92A priority patent/AU643911B2/en
Priority to MX9205370A priority patent/MX9205370A/es
Priority to ES92921317T priority patent/ES2137951T3/es
Priority to DE69229916T priority patent/DE69229916T2/de
Priority to EP92921317A priority patent/EP0605638B1/fr
Priority to RU9494019168A priority patent/RU2098413C1/ru
Priority to PCT/US1992/007952 priority patent/WO1993006094A1/fr
Priority to DK92921317T priority patent/DK0605638T3/da
Priority to CZ1994662A priority patent/CZ289299B6/cs
Priority to JP50627793A priority patent/JP3320416B2/ja
Priority to CA002098568A priority patent/CA2098568C/fr
Priority to US07/949,066 priority patent/US5274124A/en
Priority to SG1996005624A priority patent/SG63594A1/en
Priority to AT92921317T priority patent/ATE184004T1/de
Priority to HU9400831A priority patent/HU225914B1/hu
Priority to UA94005359A priority patent/UA41287C2/uk
Priority to CN92112482A priority patent/CN1058714C/zh
Priority to NZ244458A priority patent/NZ244458A/en
Priority to TW081108376A priority patent/TW368502B/zh
Priority to US08/034,247 priority patent/US5430160A/en
Priority to EG18993A priority patent/EG20320A/xx
Publication of US5229526A publication Critical patent/US5229526A/en
Application granted granted Critical
Priority to NO941020A priority patent/NO305120B1/no
Priority to FI941323A priority patent/FI109796B/fi
Priority to US08/476,357 priority patent/US5717115A/en
Priority to GR990402796T priority patent/GR3031704T3/el
Priority to US09/516,870 priority patent/US6458977B1/en
Priority to US09/566,970 priority patent/US6495704B1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Assignors: FLORIDA STATE UNIVERSITY
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Definitions

  • the present invention is directed to novel metal alkoxides useful in the preparation of derivatives of baccatin III and 10-deacetyl baccatin III such as taxol, taxotere and other taxane derivatives which have biological activity.
  • Taxol is a promising cancer chemotherapeutic agent with a broad spectrum of antileukemic and tumor-inhibiting activity. Taxol has the following structure: ##STR2## Because of this promising activity, taxol is currently undergoing clinical trials in both France and the United States.
  • Taxus brevifolia (Western Yew).
  • taxol is found only in minute quantities in the bark of these slow growing evergreens, causing considerable concern that the limited supply of taxol will not meet the demand. Consequently, chemists in recent years have expended their energies in trying to find a viable synthetic route for the preparation of taxols. So far, the results have not been entirely satisfactory.
  • 10-deacetyl baccatin III is converted to taxol by attachment of the C-10 acetyl group and by attachment of the C-13 ⁇ -amido ester side chain through the esterification of the C-13 alcohol with a ⁇ -amido carboxylic acid unit.
  • this approach requires relatively few steps, the synthesis of the ⁇ -amido carboxylic acid unit is a multi-step process which proceeds in low yield, and the coupling reaction is tedious and also proceeds in low yield.
  • this coupling reaction is a key step which is required in every contemplated synthesis of taxol or biologically active derivative of taxol, since it has been shown by Wani, et al. in JACS 93, 2325 (1971) that the presence of the ⁇ -amido ester side chain at C13 is required for anti-tumor activity.
  • taxol derivatives of the formula III below have an activity significantly greater than that of taxol (I).
  • R' represents hydrogen or acetyl and one of R" and R'" represents hydroxy and the other represents tert-butoxycarbonylamino and their stereoisomeric forms, and mixtures thereof.
  • Denis et al. disclose a different process for preparing derivatives of baccatin III or of 10-deactylbaccatin III of general formula ##STR6## in which R' denotes hydrogen or acetyl wherein an acid of general formula: ##STR7## in which R 1 is a hydroxy-protecting group, is condensed with a taxane derivative of general formula: ##STR8## in which R 2 is an acetyl hydroxy-protecting group and R 3 is a hydroxy-protecting group, and the protecting groups R 1 , R 3 and, where appropriate, R 2 are then replaced by hydrogen.
  • this method employs relatively harsh conditions, proceeds with poor conversion, and provides less than optimal yields.
  • a major difficulty remaining in the synthesis of taxol and other potential anti-tumor agents is the lack of baccatin III and 10-deacetyl baccatin III derivatives which have been activated at the C-13 oxygen. Development of such derivatives would permit attachment of the ⁇ -amido ester side chain in high yield and thus, facilitate the synthesis of taxol as well as related anti-tumor agents having a modified set of nuclear substituents or a modified C-13 side chain.
  • the present invention is directed to a metal alkoxide having the formula: ##STR9## wherein T 1 is hydrogen or a hydroxy protecting group, Z is --OT 2 , or --OCOCH 3 , T 2 is hydrogen or a hydroxy protecting group, and M is a metal, preferably, Li, Mg, Na, K or Ti.
  • Metal alkoxides (1) are activated derivatives of baccatin III and/or 10-deacetyl baccatin III and have particular utility in a process for the preparation of taxol, taxotere and other biologically active taxane derivatives.
  • metal alkoxides (1) are reacted with ⁇ -lactam (2) to form a ⁇ -amido ester intermediate. The intermediate is then converted to a biologically active taxane derivative.
  • ⁇ -lactam (2) has the general formula: ##STR10## wherein R 1 is --OR 6 , --SR 7 , or --NR 8 R 9 ;
  • R 2 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl
  • R 3 and R 4 are independently hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, or acyl, provided, however, that R 3 and R 4 are not both acyl;
  • R 5 is --COR 10 , --COOR 10 , --COSR 10 , --CONR 8 R 10 , --SO 2 R 11 , or --POR 12 R 13 ;
  • R 6 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or hydroxy protecting group
  • R 7 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, or sulfhydryl protecting group
  • R 8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl
  • R 9 is an amino protecting group
  • R 10 is alkyl, alkenyl, alkynyl, aryl, or heteroaryl;
  • R 11 is alkyl, alkenyl, alkynyl, aryl, heteroaryl, --OR 10 , or --NR 8 R 14 ;
  • R 12 and R 13 are independently alkyl, alkenyl, alkynyl, aryl, heteroaryl, --OR 10 , or --NR 8 R 14 ;
  • R 14 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl.
  • R 5 of ⁇ -lactam (2) is preferably --COR 10 with R 10 being aryl, p-substituted phenyl, or lower alkoxy, and most preferably, phenyl, methoxy, ethoxy, tert-butoxy ("tBuO"; (CH 3 ) 3 CO--) or ##STR11## wherein X is Cl, Br, F, CH 3 O--, or NO 2 --.
  • R 2 and R 4 are hydrogen or lower alkyl.
  • R 3 is preferably aryl, most preferably, naphthyl, phenyl, ##STR12## wherein X is as previously defined, Me is methyl and Ph is phenyl.
  • R 1 is selected from --OR 6 , --SR 7 or --NR 8 R 9 wherein R 6 , R 7 and R 9 , are hydroxy, sulfhydryl, and amine protecting groups, respectively, and R 8 is hydrogen, alkyl, alkenyl, alkynyl, aryl, or heteroaryl.
  • R 1 is --OR 6 wherein R 6 is triethylsilyl ("TES"), 1-ethoxyethyl (“EE”) or 2,2,2-trichloroethoxymethyl.
  • the ⁇ -lactam alkyl groups are preferably lower alkyl containing from one to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, aryl, hexyl, and the like.
  • the ⁇ -lactam alkenyl groups are preferably lower alkenyl containing from two to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, aryl, hexenyl, and the like.
  • the ⁇ -lactam alkynyl groups are preferably lower alkynyl containing from two to six carbon atoms in the principal chain and up to 15 carbon atoms. They may be straight or branched chain and include ethynyl, propynyl, butynyl, isobutynyl, aryl, hexynyl, and the like.
  • ⁇ -lactam aryl moieties described contain from 6 to 15 carbon atoms and include phenyl, ⁇ -naphthyl or ⁇ -naphthyl, etc.
  • Substituents include alkanoxy, protected hydroxy, halogen, alkyl, aryl, alkenyl, acyl, acyloxy, nitro, amino, amido, etc. Phenyl is the more preferred aryl.
  • R 1 of ⁇ -lactam (2) may be -OR 6 with R 6 being alkyl, acyl, ethoxyethyl ("EE"), triethylsilyl ("TES”), 2,2,2-trichloroethoxymethyl, or other hydroxyl protecting group such as acetals and ethers, i.e., methoxymethyl (“MOM”), benzyloxymethyl; esters, such as acetates; carbonates, such as methyl carbonates; and alkyl and aryl silyl such as triethylsilyl, trimethylsilyl, dimethyl-t-butylsilyl, dimethylarylsilyl, dimethylheteroarylsilyl, and triisopropylsilyl, and the like.
  • R 6 being alkyl, acyl, ethoxyethyl (“EE”), triethylsilyl ("TES”), 2,2,2-trichloroethoxymethyl, or other hydroxyl protecting group
  • hydroxyl protecting group for the hydroxyl group and the synthesis thereof may be found in "Protective Groups in Organic Synthesis" by T. W. Greene, John Wiley and Sons, 1981.
  • the hydroxyl protecting group selected should be easily removed under conditions that are sufficiently mild, e.g., in 48% HF, acetonitrile, pyridine, or 0.5% HCl/water/ethanol, and/or zinc, acetic acid so as not to disturb the ester linkage or other substituents of the taxol intermediate.
  • R 7 may be a sulfhydryl protecting group and R 9 may be an amine protecting group.
  • Sulfhydryl protecting groups include hemithioacetals such as 1-ethoxyethyl and methoxymethyl, thioesters, or thiocarbonates.
  • Amine protecting groups include carbamates, for example, 2,2,2-trichloroethylcarbamate or tertbutylcarbamate.
  • a variety of sulfhydryl and amine protecting groups may be found in the above-identified text by T. W. Greene.
  • ⁇ -lactams (2) can be prepared from readily available materials, as is illustrated in schemes A and B below: ##STR13## reagents: (a) triethylamine, CH 2 Cl 2 , 25° C., 18 h; (b) 4 equiv ceric ammonium nitrate, CH 3 CN, -10° C., 10 min; (c) KOH, THF, H 2 O, 0° C., 30 min; (d) ethyl vinyl ether, THF, toluene sulfonic acid (cat.), 0° C., 1.5 h; (e) n-butyllithium, ether, -78° C., 10 min; benzoyl chloride, -78° C., 1 h; (f) lithium diisopropyl amide, THF -78° C. to -50° C.; (g) lithium hexamethyldisilazide, THF -78° C. to 0°
  • ⁇ -Acyloxy acetyl chloride is prepared from glycolic acid, and, in the presence of a tertiary amine, it cyclocondenses with imines prepared from aldehydes and p-methoxyaniline to give 1-p-methoxyphenyl-3-acyloxy-4-arylazetidin-2-ones.
  • the p-methoxyphenyl group can be readily removed through oxidation with ceric ammonium nitrate, and the acyloxy group can be hydrolyzed under standard conditions familiar to those experienced in the art to provide 3-hydroxy-4-arylazetidin-2-ones.
  • the 3-hydroxyl group is protected with 1-ethoxyethyl, but may be protected with variety of standard protecting groups such as the triethylsilyl group or other trialkyl (or aryl) silyl groups.
  • ethyl- ⁇ -triethylsilyloxyacetate is readily prepared from glycolic acid.
  • racemic ⁇ -lactams may be resolved into the pure enantiomers prior to protection by recrystallization of the corresponding 2-methoxy-2-(trifluoromethyl) phenylacetic esters.
  • the reaction described hereinbelow in which the ⁇ -amido ester side chain is attached has the advantage of being highly diastereoselective, thus permitting the use of a racemic mixture of side chain precursor.
  • the 3-(1-ethoxyethoxy)-4-phenylazetidin-2-one of Scheme A and the 3-(1-triethylsilyl)-4-phenylazetidin-2-one of Scheme B can be converted to ⁇ -lactam (2), by treatment with a base, preferably n-butyllithium, and an acyl chloride, sulfonyl chloride, phosphinyl chloride, phosphoryl chloride or an alkyl chloroformate at -78° C. or less.
  • the metal alkoxides are prepared by reacting an alcohol having two to four rings of the taxane nucleus and a C-13 hydroxyl group with an organometallic compound in a suitable solvent.
  • the alcohol is a protected baccatin III, in particular, 7-O-triethylsilyl baccatin III (which can be obtained as described by Greene, et al. in JACS 110, 5917 (1988) or by other routes) or 7,10-bis-O-triethylsilyl baccatin III.
  • 10-deacetyl baccatin III is converted to 7-O-triethylsilyl-10-deacetyl baccatin III according to the following reaction scheme: ##STR14## Under what is reported to be carefully optimized conditions, 10-deacetyl baccatin III is reacted with 20 equivalents of (C 2 H 5 ) 3 SiCl at 23° C. under an argon atmosphere for 20 hours in the presence of 50 ml of pyridine/mmol of 10-deacetyl baccatin III to provide 7-triethylsilyl-10-deacetyl baccatin III (4a) as a reaction product in 84-86% yield after purification.
  • reaction product (4a) is then acetylated with 5 equivalents of CH 3 COCl and 25 mL of pyridine/mmol of 4a at 0° C. under an argon atmosphere for 48 hours to provide 86% yield of 7-O-triethylsilyl baccatin III (4b) as reported by Greene, et al. in JACS 110, 5917 at 5918 (1988).
  • 7-triethylsilyl-10-deacetyl baccatin III (4a) can be protected at C-10 oxygen with an acid labile hydroxyl protecting group.
  • treatment of (4a) with n-butyllithium in THF followed by triethylsilyl chloride (1.1 mol equiv.) at 0° C. gives 7,10-bis-O-triethylsilyl baccatin III (4c) in 95% yield.
  • (4a) can be converted to 7-O-treithylsilyl-10-(1-ethoxyethyl) baccatin III (4d) in 90% yield by treatment with excess ethyl vinyl ether and a catalytic amount of methane sulfonic acid.
  • the 7-O-triethylsilyl baccatin III derivatives (4b, 4c or 4d) are reacted with an organometallic compound such as n-butyllithium in a solvent such as tetrahydrofuran (THF), to form the metal alkoxide 13-O-lithium-7-O-triethylsilyl baccatin III derivative (5b, 5c or 5d) as shown in the following reaction scheme: ##STR16##
  • the 13-O-lithium-7-O-triethylsilyl baccatin III derivative (b, 5c, or 5d) reacts with ⁇ -lactam (2) to provide an intermediate (6b, 6c, or 6d) in which the C-7 and C-2' hydroxyl groups are protected with a triethylsilyl group.
  • the triethylsilyl and ethoxyethyl groups are then hydrolyzed under mild conditions so as not to disturb the ester linkage or the taxane substituents.
  • the 7-O-triethylsilyl baccatin III derivatives (4b, 4c or 4d) are reacted with an organometallic compound such as n-butyllithium in a solvent such as tetrahydrofuran (THF), to form the metal alkoxide 13-O-lithium-7-O-triethylsilyl baccatin III derivative (5b, 5c or 5d) as shown in the following reaction scheme: ##STR17##
  • the 13-O-lithium-7-O-triethylsilyl baccatin III derivative (b, 5c, or 5d) reacts with ⁇ -lactam (2) to provide an intermediate (6b, 6c, or 6d) in which the C-7 and C-2' hydroxyl groups are protected with a triethylsilyl group.
  • the triethylsilyl and ethoxyethyl groups are then hydrolyzed under mild conditions so as not to disturb the ester linkage or the taxane substituents.
  • T 1 is a hydroxy protecting group
  • M is a metal
  • Ph is phenyl
  • Ac is acetyl
  • R 1 to R 5 are as previously defined.
  • Metal substituent, M, of metal alkoxide (3) is a Group IA, IIA, IIIA, lanthanide or actinide element or a transition, Group IIIA, IVA, VA or VIA metal.
  • it is a Group IA, IIA or transition metal, and most preferably, it is lithium, magnesium, sodium, potassium or titanium.
  • Both the conversion of the alcohol to the metal alkoxide and the ultimate synthesis of the taxane derivative can take place in the same reaction vessel.
  • the ⁇ -lactam is added to the reaction vessel after formation therein of the metal alkoxide.
  • the organometallic compound n-butyllithium is preferably used to convert baccatin III or 10-deacetyl baccatin III to the corresponding metal alkoxide, but other sources of metallic substituent such as lithium diisopropyl amide, other lithium or magnesium amides, ethylmagnesium bromide, methylmagnesium bromide, other organolithium compounds, other organomagnesium compounds, organosodium, organotitanium or organopotassium may also be used.
  • Organometallic compounds are readily available, or may be prepared by available methods including reduction of organic halides with metal. For example, butyl bromide can be reacted with lithium metal in diethyl ether to give a solution of n-butyllithium in the following manner: ##STR19##
  • THF is the preferred solvent for the reaction mixture
  • other ethereal solvents such as dimethoxyethane, or aromatic solvents may also be suitable.
  • Other solvents are not appropriate for other reasons. For example, esters are not appropriate for use with certain organometallic compounds such as n-butyllithium due to incompatibility therewith.
  • the reaction scheme disclosed herein is ideally directed to the synthesis of taxol, taxotere, and other taxane derivatives exemplified herein, it can be used with modifications in either the ⁇ -lactam or the tetracyclic metal alkoxide to produce other compounds.
  • the ⁇ -lactam and the tetracyclic metal alkoxide can be derived from natural or unnatural sources, to prepare other synthetic taxols, taxol derivatives, 10-deacetyltaxols, and the enantiomers and diastereomers thereof contemplated within the present invention.
  • the process of the invention also has the important advantage of being highly diastereoselective. Therefore racemic mixtures of the side chain precursors may be used. Substantial cost savings may be realized because there is no need to resolve racemic ⁇ -lactams into their pure enantiomers. Additional cost savings may be realized because less side chain precursor, e.g., 60-70% less, is required relative to prior processes.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Glass Compositions (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Compositions Of Oxide Ceramics (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Saccharide Compounds (AREA)
US07/862,778 1991-09-23 1992-04-03 Metal alkoxides Expired - Lifetime US5229526A (en)

Priority Applications (32)

Application Number Priority Date Filing Date Title
US07/862,778 US5229526A (en) 1991-09-23 1992-04-03 Metal alkoxides
IL103192A IL103192A (en) 1991-09-23 1992-09-16 Metal alkoxides
PH44959A PH30213A (en) 1991-09-23 1992-09-21 Metal alkoxides
PT100884A PT100884B (pt) 1991-09-23 1992-09-21 Alcoxidos de metal uteis na preparacao de derivados taxano
MYPI92001683A MY128481A (en) 1991-09-23 1992-09-21 Semi-synthesis of taxane derivatives using metal alkoxides and beta-lactams.
MX9205370A MX9205370A (es) 1991-09-23 1992-09-22 Alcoxidos metalicos.
SG1996005624A SG63594A1 (en) 1991-09-23 1992-09-22 Metal alkoxides
UA94005359A UA41287C2 (uk) 1991-09-23 1992-09-22 Алкоголяти металів для отримання похідних таксану
ES92921317T ES2137951T3 (es) 1991-09-23 1992-09-22 Alcoxidos de metales.
DE69229916T DE69229916T2 (de) 1991-09-23 1992-09-22 Metallalkoxide
EP92921317A EP0605638B1 (fr) 1991-09-23 1992-09-22 Alcoxydes de metaux
RU9494019168A RU2098413C1 (ru) 1991-09-23 1992-09-22 Алкоголяты металлов
PCT/US1992/007952 WO1993006094A1 (fr) 1991-09-23 1992-09-22 Alcoxydes de metaux
DK92921317T DK0605638T3 (da) 1991-09-23 1992-09-22 Metalalkoxider
CZ1994662A CZ289299B6 (cs) 1991-09-23 1992-09-22 Alkoxidy kovů
JP50627793A JP3320416B2 (ja) 1991-09-23 1992-09-22 金属アルコキシド
CA002098568A CA2098568C (fr) 1991-09-23 1992-09-22 Alcoxydes de metal
US07/949,066 US5274124A (en) 1991-09-23 1992-09-22 Metal alkoxides
AU26888/92A AU643911B2 (en) 1991-09-23 1992-09-22 Metal alkoxides
AT92921317T ATE184004T1 (de) 1991-09-23 1992-09-22 Metallalkoxide
HU9400831A HU225914B1 (en) 1991-09-23 1992-09-22 Process for producing of new metal alkoxides
CN92112482A CN1058714C (zh) 1991-09-23 1992-09-23 金属醇盐的制备方法
NZ244458A NZ244458A (en) 1991-09-23 1992-09-23 Metal alkoxides of taxane derivatives
TW081108376A TW368502B (en) 1991-09-23 1992-10-21 Metal alkoxides
US08/034,247 US5430160A (en) 1991-09-23 1993-03-22 Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
EG18993A EG20320A (en) 1992-04-03 1993-03-30 Process for preparing of metal alkoxides
NO941020A NO305120B1 (no) 1991-09-23 1994-03-22 Metallalkoksider
FI941323A FI109796B (fi) 1991-09-23 1994-03-22 Metallialkoksidit
US08/476,357 US5717115A (en) 1991-09-23 1995-06-07 Metal alkoxides and ammonium alkoxides
GR990402796T GR3031704T3 (en) 1991-09-23 1999-11-03 Metal alkoxides.
US09/516,870 US6458977B1 (en) 1991-09-23 2000-03-02 Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
US09/566,970 US6495704B1 (en) 1991-09-23 2000-05-09 9-desoxotaxanes and process for the preparation of 9-desoxotaxanes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76380591A 1991-09-23 1991-09-23
US07/862,778 US5229526A (en) 1991-09-23 1992-04-03 Metal alkoxides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US76380591A Continuation-In-Part 1991-09-23 1991-09-23

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US76380591A Continuation-In-Part 1991-09-23 1991-09-23
US07/949,066 Continuation-In-Part US5274124A (en) 1991-09-23 1992-09-22 Metal alkoxides
US08/034,247 Continuation-In-Part US5430160A (en) 1991-09-23 1993-03-22 Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides
US08/476,357 Continuation-In-Part US5717115A (en) 1991-09-23 1995-06-07 Metal alkoxides and ammonium alkoxides

Publications (1)

Publication Number Publication Date
US5229526A true US5229526A (en) 1993-07-20

Family

ID=27117339

Family Applications (1)

Application Number Title Priority Date Filing Date
US07/862,778 Expired - Lifetime US5229526A (en) 1991-09-23 1992-04-03 Metal alkoxides

Country Status (24)

Country Link
US (1) US5229526A (fr)
EP (1) EP0605638B1 (fr)
JP (1) JP3320416B2 (fr)
CN (1) CN1058714C (fr)
AT (1) ATE184004T1 (fr)
AU (1) AU643911B2 (fr)
CA (1) CA2098568C (fr)
CZ (1) CZ289299B6 (fr)
DE (1) DE69229916T2 (fr)
DK (1) DK0605638T3 (fr)
ES (1) ES2137951T3 (fr)
FI (1) FI109796B (fr)
HU (1) HU225914B1 (fr)
IL (1) IL103192A (fr)
MX (1) MX9205370A (fr)
MY (1) MY128481A (fr)
NO (1) NO305120B1 (fr)
NZ (1) NZ244458A (fr)
PH (1) PH30213A (fr)
PT (1) PT100884B (fr)
RU (1) RU2098413C1 (fr)
TW (1) TW368502B (fr)
UA (1) UA41287C2 (fr)
WO (1) WO1993006094A1 (fr)

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994015929A1 (fr) * 1993-01-15 1994-07-21 Florida State University Procede de preparation de desacetoxy-10 baccatine-iii
WO1994021252A1 (fr) * 1993-03-22 1994-09-29 Florida State University Taxanes ayant une chaine laterale a substitution pyridyle
WO1994021623A1 (fr) * 1993-03-22 1994-09-29 Florida State University Taxanes prepares a l'aide beta-lactames et d'alcoxydes d'ammonium
US5380751A (en) * 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
US5405972A (en) * 1993-07-20 1995-04-11 Florida State University Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes
US5407674A (en) * 1993-05-20 1995-04-18 Indena S.P.A. Taxane having antitumor activity
EP0694539A1 (fr) 1994-07-28 1996-01-31 Bristol-Myers Squibb Company 7-0-éthers de dérivés de taxane
US5489601A (en) * 1991-09-23 1996-02-06 Florida State University Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US5547981A (en) * 1993-03-09 1996-08-20 Enzon, Inc. Taxol-7-carbazates
US5606083A (en) * 1992-11-23 1997-02-25 Rhone-Poulenc Rorer S.A. Process for the preparation of taxane derivatives, new derivatives thus obtained and the compositions which contain them
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5622986A (en) * 1993-10-20 1997-04-22 Enzon, Inc. 2'-and/or 7-substituted taxanes
US5635531A (en) * 1996-07-08 1997-06-03 Bristol-Myers Squibb Company 3'-aminocarbonyloxy paclitaxels
US5646176A (en) * 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US5654448A (en) * 1995-10-02 1997-08-05 Xechem International, Inc. Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes
WO1997032578A1 (fr) * 1996-03-04 1997-09-12 The Research Foundation Of State University Of New York Agent antitumoraux taxoides et compositions pharmaceutiques contenant de tels agents
EP0797988A2 (fr) 1993-07-19 1997-10-01 Angiotech Pharmaceuticals, Inc. Compositions anti-angiogéniques et leurs procédés d'utilisation
WO1997042181A1 (fr) * 1996-05-06 1997-11-13 Florida State University 1-deoxy baccatine iii, 1-deoxy taxol, analogues de 1-deoxy taxol, et procedes de fabrication correspondants
US5710287A (en) * 1991-09-23 1998-01-20 Florida State University Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
WO1998002427A1 (fr) * 1996-07-11 1998-01-22 Napro Biotherapeutics, Inc. Procede d'acylation selective de 10-desacetylbaccatine iii en position c-10
US5714513A (en) * 1991-09-23 1998-02-03 Florida State University C10 taxane derivatives and pharmaceutical compositions
US5721268A (en) * 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5723634A (en) * 1991-09-23 1998-03-03 Florida State University Metal alkoxide compounds
US5728725A (en) * 1991-09-23 1998-03-17 Florida State University C2 taxane derivaties and pharmaceutical compositions containing them
US5728850A (en) * 1991-09-23 1998-03-17 Florida State University Taxanes having a butenyl substituted side-chain and pharmaceutical compositions containing them
US5739362A (en) * 1991-09-23 1998-04-14 Florida State University Taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US5760251A (en) * 1995-08-11 1998-06-02 Sepracor, Inc. Taxol process and compounds
AU694941B2 (en) * 1993-08-17 1998-08-06 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US5807888A (en) * 1995-12-13 1998-09-15 Xechem International, Inc. Preparation of brominated paclitaxel analogues and their use as effective antitumor agents
US5840930A (en) * 1995-10-02 1998-11-24 Xechem International, Inc. Method for production of 2", 3" dihalocephalomannine
US5847170A (en) * 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US5854278A (en) * 1995-12-13 1998-12-29 Xechem International, Inc. Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5912264A (en) * 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
US5914411A (en) * 1998-01-21 1999-06-22 Napro Biotherapeutics, Inc. Alternate method for acylating 10-deacetylbaccatin III selectively at the C-10 position
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5973170A (en) * 1996-09-25 1999-10-26 Napro Biotherapuetics, Inc. C-7 metal alkoxides of baccatin III
US5998656A (en) * 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US6005120A (en) * 1993-07-20 1999-12-21 Florida State University Tricyclic and tetracyclic taxanes
US6008385A (en) * 1993-03-22 1999-12-28 Rhone-Poulenc Rorer S.A. Process for the purification of taxoids
US6011056A (en) * 1991-09-23 2000-01-04 Florida State University C9 taxane derivatives and pharmaceutical compositions containing them
US6018073A (en) * 1991-09-23 2000-01-25 Florida State University Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US6017935A (en) * 1997-04-24 2000-01-25 Bristol-Myers Squibb Company 7-sulfur substituted paclitaxels
US6022985A (en) * 1994-07-08 2000-02-08 Rhone-Poulenc Rorer S.A. Process for the preparation of 4-acetoxy-2α-benzoyloxy-5β, 20-epoxy-1, 7β-10β-trihydroxy-9-oxo-tax-11-en-13α-yl(2R,3S)-3-tert-b utoxy-carbonYlamino-2-hydroxy-3-phenylpropionate trihydrate
US6025516A (en) * 1998-10-14 2000-02-15 Chiragene, Inc. Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
US6028205A (en) * 1991-09-23 2000-02-22 Florida State University C2 tricyclic taxanes
US6048990A (en) * 1998-05-01 2000-04-11 Napro Biotherapeutics, Inc. Method for selective acylation of C-2'-O-protected-10-hydroxy-taxol at the C-10 position
US6066747A (en) * 1993-03-05 2000-05-23 Florida State University Process for the preparation of 9-desoxotaxanes
US6066749A (en) * 1998-05-01 2000-05-23 Napro Biotherapeutics, Inc. Method for conversion of C-2'-O-protected-10-hydroxy taxol to c-2'-O-protected taxol:useful intermediates in paclitaxel synthesis
US6096909A (en) * 1994-10-28 2000-08-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6133462A (en) * 1996-09-25 2000-10-17 Napro Biotherapeutics, Inc. C-7 CBZ baccatin III and production method therefor
US6136999A (en) * 1999-06-21 2000-10-24 Napro Biotherapeutics, Inc. C-2 hydroxyl protected-n-acyl (2R,3S)-3-phenylisoserine substituted phenyl activated esters and method for production thereof
US6143902A (en) * 1999-06-21 2000-11-07 Napro Biotherapeutics, Inc. C-2 hydroxyl protected-N-acyl (2R,3S)-3-phenylisoserine N-imido activated esters and method for production thereof
US6156789A (en) * 1998-03-17 2000-12-05 Rhone-Poulenc Rorer S.A. Method for treating abnormal cell proliferation in the brain
US6177456B1 (en) 1995-10-02 2001-01-23 Xechem International, Inc. Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor
US6187916B1 (en) * 1993-02-01 2001-02-13 Research Foundation Of State University Of New York Process for the preparation of taxane derivatives and β-lactam intermediates therefor
US6310201B1 (en) 1993-03-19 2001-10-30 Bristol-Myers Squibb Company β-lactams, methods for the preparation of taxanes, and sidechain-bearing taxanes
EP0956284A4 (fr) * 1997-08-18 2001-12-05 Univ Florida State Procede de derivatisation selective de taxanes
US6331635B1 (en) 1995-03-27 2001-12-18 Aventis Pharma S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US6335362B1 (en) 1991-09-23 2002-01-01 Florida State University Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
US6395895B1 (en) 1991-09-23 2002-05-28 Florida State University Butenyl substituted β-lactams
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US6448417B1 (en) 1998-05-01 2002-09-10 Napro Biotherapeutics, Inc. Methods and useful intermediates for paclitaxel synthesis from C-7, C-10 di-cbz 10-deacetylbaccatin III
US6458976B1 (en) 1994-10-28 2002-10-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods
US6495704B1 (en) 1991-09-23 2002-12-17 Florida State University 9-desoxotaxanes and process for the preparation of 9-desoxotaxanes
US20020197245A1 (en) * 1992-11-10 2002-12-26 Aventis Pharma, S.A. Antitumour compositions containing taxane derivatives
US6500858B2 (en) 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6521660B2 (en) 1991-09-23 2003-02-18 Florida State University 3′-alkyl substituted taxanes and pharmaceutical compositions containing them
US20030069415A1 (en) * 2001-08-21 2003-04-10 Patel Ramesh N. Enzymatic resolution of t-butyl taxane derivatives
US6548293B1 (en) 1999-10-18 2003-04-15 Fsu Research Foundation, Inc. Enzymatic process for the resolution of enantiomeric mixtures of β-lactams
US6593482B2 (en) 1993-02-01 2003-07-15 Aventis Pharma S.A. Methods for preparing new taxoids and pharmaceutical compositions containing them
US20030144344A1 (en) * 2001-11-30 2003-07-31 Benigni Daniel A. Paclitaxel solvates
US6710191B2 (en) 1993-03-05 2004-03-23 Florida State University 9β-hydroxytetracyclic taxanes
US20040073048A1 (en) * 1991-09-23 2004-04-15 Florida State University Perparation of substituted isoserine esters using metal alkoxides and beta-lactams
US20040132991A1 (en) * 2002-10-09 2004-07-08 Phytogen Life Sciences Inc. Novel taxanes and methods related to use and preparation thereof
US20040142705A1 (en) * 2002-01-30 2004-07-22 Microsoft Corporation Proximity sensor with adaptive threshold
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
US20050054863A1 (en) * 2003-08-07 2005-03-10 Gibson Frank S. Process for preparing 4-alkyl- or 4-aryl-oxycarbonyl paclitaxel analogs and novel intermediates
US20050101789A1 (en) * 2003-10-27 2005-05-12 Phytogen Life Sciences Inc. Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III
US20050288520A1 (en) * 2004-06-25 2005-12-29 Phytogen Life Sciences Inc. One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel
US7074821B1 (en) 1992-12-09 2006-07-11 Aventis Pharma, S.A. Taxoids, their preparation and pharmaceutical composition containing them
US20060236917A1 (en) * 2005-04-21 2006-10-26 Atsushi Denda Method of forming conductive film and method of manufacturing electronic apparatus
US20070027207A1 (en) * 2004-06-04 2007-02-01 Ragina Naidu Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel
US20080108693A1 (en) * 2006-10-20 2008-05-08 Scinopharm Singapore Pte Ltd. Crystalline forms of docetaxel and process for preparation thereof
US20090170928A1 (en) * 2005-04-28 2009-07-02 Bruno Ferdinando F Synthesis of oligo/poly(catechins) and methods of use
US20090292131A1 (en) * 2008-05-07 2009-11-26 Ladislav Cvak Processes for preparation of taxanes and intermediates thereof
EP2266607A2 (fr) 1999-10-01 2010-12-29 Immunogen, Inc. Des immunoconjugués pour le traitement des cancers.

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA926829B (en) * 1991-09-23 1993-03-15 Univ Florida State Novel substituted taxanes and pharmaceutical compositions containing them.
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
ZA94128B (en) * 1993-02-01 1994-08-19 Univ New York State Res Found Process for the preparation of taxane derivatives and betalactam intermediates therefor
AU6367994A (en) * 1993-03-22 1994-10-11 Florida State University Taxanes having alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing same
FR2718137B1 (fr) * 1994-04-05 1996-04-26 Rhone Poulenc Rorer Sa Procédé de préparation de trialcoylsilyl-7 baccatine III.
JP2001524067A (ja) * 1995-09-13 2001-11-27 フロリダ・ステイト・ユニバーシティ 放射線感作性タキサン類およびその医薬製剤
US5917062A (en) * 1997-11-21 1999-06-29 Indena S.P.A Intermediates and methods useful in the semisynthesis of paclitaxel and analogs
CN101289432B (zh) * 2007-04-20 2010-12-15 上海天伟生物制药有限公司 异丝氨酸酯衍生物及其制备方法
KR101096282B1 (ko) 2009-04-24 2011-12-20 주식회사 삼양제넥스 탁산 유도체를 제조하는 방법

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253739A1 (fr) * 1986-07-17 1988-01-20 Rhone-Poulenc Sante Procédé de préparation du taxol et du désacétyl-10 taxol
US4814470A (en) * 1986-07-17 1989-03-21 Rhone-Poulenc Sante Taxol derivatives, their preparation and pharmaceutical compositions containing them
EP0336840A1 (fr) * 1988-04-06 1989-10-11 Centre National De La Recherche Scientifique (Cnrs) Procédé de préparation du taxol
EP0336841A1 (fr) * 1988-04-06 1989-10-11 Rhone-Poulenc Sante Procédé de préparation de dérivés de la baccatine III et de la désacétyl-10 baccatine III
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253739A1 (fr) * 1986-07-17 1988-01-20 Rhone-Poulenc Sante Procédé de préparation du taxol et du désacétyl-10 taxol
US4814470A (en) * 1986-07-17 1989-03-21 Rhone-Poulenc Sante Taxol derivatives, their preparation and pharmaceutical compositions containing them
US4857653A (en) * 1986-07-17 1989-08-15 Rhone-Poulenc Sante Process for the preparation of taxol and 10-deacetyltaxol
EP0253738B1 (fr) * 1986-07-17 1990-01-31 Rhone-Poulenc Sante Dérivés du taxol, leur préparation et les compositions pharmaceutiques qui les contiennent
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
EP0336840A1 (fr) * 1988-04-06 1989-10-11 Centre National De La Recherche Scientifique (Cnrs) Procédé de préparation du taxol
EP0336841A1 (fr) * 1988-04-06 1989-10-11 Rhone-Poulenc Sante Procédé de préparation de dérivés de la baccatine III et de la désacétyl-10 baccatine III
US4924012A (en) * 1988-04-06 1990-05-08 Rhone-Poulenc Sante Process for preparing derivatives of baccatine III and of 10-deacetyl baccatine III
US4924011A (en) * 1988-04-06 1990-05-08 Centre National De La Recherche Scientifique Process for preparing taxol
US5015744A (en) * 1989-11-14 1991-05-14 Florida State University Method for preparation of taxol using an oxazinone

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Denis and Greene, "A Highly Efficient, Practical Approach to Natural Taxol", J. Am. Chem. Soc. 1988, 110, 5917-5919.
Denis and Greene, A Highly Efficient, Practical Approach to Natural Taxol , J. Am. Chem. Soc. 1988, 110, 5917 5919. *
Holton et al., "A Synthesis of Taxusin", J. Am. Chem. Soc., 1988, 110, pp. 6558-6560.
Holton et al., A Synthesis of Taxusin , J. Am. Chem. Soc., 1988, 110, pp. 6558 6560. *
Holton, "Synthesis of the Taxane Ring System", J. Am. Chem. Soc., 1984, 106, pp. 5731-5732.
Holton, Synthesis of the Taxane Ring System , J. Am. Chem. Soc., 1984, 106, pp. 5731 5732. *
Mukerjee et al., "β-Lactams: Retrospect and Prospect", Tetrahedron vol. 34, Report No. 52, pp. 1731-1767 (1978).
Mukerjee et al., Lactams: Retrospect and Prospect , Tetrahedron vol. 34, Report No. 52, pp. 1731 1767 (1978). *
Wani et al., "Plant Antitumor Agents. VI. The Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from Taxus brevifolia", J. Am. Chem. Soc. 93:9, May 5, 1971, pp. 2325-2327.
Wani et al., Plant Antitumor Agents. VI. The Isolation and Structure of Taxol, a Novel Antileukemic and Antitumor Agent from Taxus brevifolia , J. Am. Chem. Soc. 93:9, May 5, 1971, pp. 2325 2327. *

Cited By (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018073A (en) * 1991-09-23 2000-01-25 Florida State University Tricyclic taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US5998656A (en) * 1991-09-23 1999-12-07 Florida State University C10 tricyclic taxanes
US6051724A (en) * 1991-09-23 2000-04-18 Florida State Universitiy Amino substituted taxanes
US6872842B2 (en) 1991-09-23 2005-03-29 Florida State University Butenyl substituted taxanes
US6495704B1 (en) 1991-09-23 2002-12-17 Florida State University 9-desoxotaxanes and process for the preparation of 9-desoxotaxanes
US6482963B1 (en) 1991-09-23 2002-11-19 Florida State University C9 hydrido, hydroxy and acyloxy taxane derivatives and pharmaceutical compositions containing them
US6479678B1 (en) 1991-09-23 2002-11-12 Florida State University Metal alkoxide taxane and β-lactam compounds
US6011056A (en) * 1991-09-23 2000-01-04 Florida State University C9 taxane derivatives and pharmaceutical compositions containing them
US6462208B2 (en) 1991-09-23 2002-10-08 Florida State University C7 acyloxy and hydrido taxane derivatives and pharmaceutical compositions containing them
US6069260A (en) * 1991-09-23 2000-05-30 Florida State University Metal alkoxides
US6730782B2 (en) 1991-09-23 2004-05-04 Florida State University Carbamoyl substituted β-lactams
US5489601A (en) * 1991-09-23 1996-02-06 Florida State University Taxanes having a pyridyl substituted side-chain and pharmaceutical compositions containing them
US20030187061A1 (en) * 1991-09-23 2003-10-02 Florida State University Beta-lactams having an alkyl-substituted side chain
US6028205A (en) * 1991-09-23 2000-02-22 Florida State University C2 tricyclic taxanes
US6395895B1 (en) 1991-09-23 2002-05-28 Florida State University Butenyl substituted β-lactams
US6521660B2 (en) 1991-09-23 2003-02-18 Florida State University 3′-alkyl substituted taxanes and pharmaceutical compositions containing them
US6797833B2 (en) 1991-09-23 2004-09-28 Florida State University C9 hydrido and acyloxy metal alkoxides
US6335362B1 (en) 1991-09-23 2002-01-01 Florida State University Taxanes having an alkyl substituted side-chain and pharmaceutical compositions containing them
US5994576A (en) * 1991-09-23 1999-11-30 Florida State University C7 tricyclic taxanes
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
US7074945B2 (en) 1991-09-23 2006-07-11 Florida State University Metal alkoxide taxane derivatives
US5710287A (en) * 1991-09-23 1998-01-20 Florida State University Taxanes having an amino substituted side-chain and pharmaceutical compositions containing them
US6762309B2 (en) 1991-09-23 2004-07-13 Florida State University C7 acyloxy metal alkoxides
US5714513A (en) * 1991-09-23 1998-02-03 Florida State University C10 taxane derivatives and pharmaceutical compositions
US5717115A (en) * 1991-09-23 1998-02-10 Florida State University Metal alkoxides and ammonium alkoxides
US5721268A (en) * 1991-09-23 1998-02-24 Florida State University C7 taxane derivatives and pharmaceutical compositions containing them
US5723634A (en) * 1991-09-23 1998-03-03 Florida State University Metal alkoxide compounds
US5728725A (en) * 1991-09-23 1998-03-17 Florida State University C2 taxane derivaties and pharmaceutical compositions containing them
US5728850A (en) * 1991-09-23 1998-03-17 Florida State University Taxanes having a butenyl substituted side-chain and pharmaceutical compositions containing them
US5739362A (en) * 1991-09-23 1998-04-14 Florida State University Taxanes having an alkoxy, alkenoxy or aryloxy substituted side-chain and pharmaceutical compositions containing them
US6369244B1 (en) 1991-09-23 2002-04-09 Florida State University C13 amido substituted taxane derivatives and pharmaceutical compositions containing them
US5760219A (en) * 1991-09-23 1998-06-02 Florida State University Pyridyl substituted B-lactam compounds
US6683196B2 (en) 1991-09-23 2004-01-27 Florida State University Process for the preparation of metal alkoxides
US20040073048A1 (en) * 1991-09-23 2004-04-15 Florida State University Perparation of substituted isoserine esters using metal alkoxides and beta-lactams
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US8124650B2 (en) 1992-11-10 2012-02-28 Aventis Pharma S.A. Antitumor combinations containing taxane derivatives and epidophyllotoxins
US7989489B2 (en) 1992-11-10 2011-08-02 Aventis Pharma S.A. Method of treating leukemia with docetaxel and vinca alkaloids
US20040152643A1 (en) * 1992-11-10 2004-08-05 Aventis Pharma S.A. Antitumour combinations containing taxane derivatives and antimetabolites
US20020197245A1 (en) * 1992-11-10 2002-12-26 Aventis Pharma, S.A. Antitumour compositions containing taxane derivatives
US8101652B2 (en) 1992-11-10 2012-01-24 Aventis Pharma S.A. Antitumour combinations containing taxotere and 5-fluorouracil
US20040152673A1 (en) * 1992-11-10 2004-08-05 Aventis Pharma S.A. Antitumor combinations containing taxane derivatives and alkylating agents
US20040152644A1 (en) * 1992-11-10 2004-08-05 Aventis Pharma S.A. Antitumor combinations containing taxane derivatives and epidophyllotoxins
US20050226940A1 (en) * 1992-11-10 2005-10-13 Aventis Pharma, S.A. Antitumour compositions containing taxane derivatives
US20040152642A1 (en) * 1992-11-10 2004-08-05 Aventis Pharma S.A. Antitumor combinations containing taxane derivatives and antibiotics
US7994212B2 (en) 1992-11-10 2011-08-09 Aventis Pharma S.A. Method of treating cancer with docetaxel and doxorubicin
US20040013660A1 (en) * 1992-11-10 2004-01-22 Aventis Pharma S.A. Antitumour compositions containing taxane derivatives
US5606083A (en) * 1992-11-23 1997-02-25 Rhone-Poulenc Rorer S.A. Process for the preparation of taxane derivatives, new derivatives thus obtained and the compositions which contain them
US5380751A (en) * 1992-12-04 1995-01-10 Bristol-Myers Squibb Company 6,7-modified paclitaxels
US5693666A (en) * 1992-12-04 1997-12-02 Bristol-Myers Squibb Company 6,7-modified paclitaxels
US7074821B1 (en) 1992-12-09 2006-07-11 Aventis Pharma, S.A. Taxoids, their preparation and pharmaceutical composition containing them
US5646176A (en) * 1992-12-24 1997-07-08 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US6455575B2 (en) 1992-12-24 2002-09-24 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
WO1994015929A1 (fr) * 1993-01-15 1994-07-21 Florida State University Procede de preparation de desacetoxy-10 baccatine-iii
US6187916B1 (en) * 1993-02-01 2001-02-13 Research Foundation Of State University Of New York Process for the preparation of taxane derivatives and β-lactam intermediates therefor
US6593482B2 (en) 1993-02-01 2003-07-15 Aventis Pharma S.A. Methods for preparing new taxoids and pharmaceutical compositions containing them
US6710191B2 (en) 1993-03-05 2004-03-23 Florida State University 9β-hydroxytetracyclic taxanes
US20040192944A1 (en) * 1993-03-05 2004-09-30 Florida State University 14-Hydrido-9beta-hydroxytetracyclic taxanes
US6066747A (en) * 1993-03-05 2000-05-23 Florida State University Process for the preparation of 9-desoxotaxanes
US6878834B2 (en) 1993-03-05 2005-04-12 Florida State University 14-hydrido-9β-hydroxytetracyclic taxanes
US5547981A (en) * 1993-03-09 1996-08-20 Enzon, Inc. Taxol-7-carbazates
US6350887B1 (en) 1993-03-19 2002-02-26 Bristol-Myers Squibb Company β-lactams, methods for the preparation of taxanes, and sidechain-bearing taxanes
US6350886B1 (en) * 1993-03-19 2002-02-26 Bristol-Myers Squibb Company β-lactams, methods for the preparation of taxanes, and sidechain-bearing taxanes
US7176326B2 (en) 1993-03-19 2007-02-13 Bristol-Myers Squibb Company β-Lactams, methods for the preparation of taxanes, and sidechain-bearing taxanes
US20050107605A1 (en) * 1993-03-19 2005-05-19 Bristol-Myers Squibb Company Novel beta-lactams methods for the preparation of taxanes, and sidechain-bearing taxanes
US6310201B1 (en) 1993-03-19 2001-10-30 Bristol-Myers Squibb Company β-lactams, methods for the preparation of taxanes, and sidechain-bearing taxanes
WO1994021252A1 (fr) * 1993-03-22 1994-09-29 Florida State University Taxanes ayant une chaine laterale a substitution pyridyle
WO1994021623A1 (fr) * 1993-03-22 1994-09-29 Florida State University Taxanes prepares a l'aide beta-lactames et d'alcoxydes d'ammonium
US6197980B1 (en) 1993-03-22 2001-03-06 Rhone-Poulenc Rorer S.A. 4-Acetoxy-2α-benzoyloxy-5β,20-epoxy-1β,7β,10β-trihydroxy-9-oxo-11-taxen-13α-yl(2R,3S)-3-t-butoxycarbonylamino-3-phenyl-2-hydroxypropionate trihydrate
US6124481A (en) * 1993-03-22 2000-09-26 Florida State University Ammonium alkoxides
US6008385A (en) * 1993-03-22 1999-12-28 Rhone-Poulenc Rorer S.A. Process for the purification of taxoids
US5407674A (en) * 1993-05-20 1995-04-18 Indena S.P.A. Taxane having antitumor activity
US20070003630A1 (en) * 1993-07-19 2007-01-04 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
EP0797988A2 (fr) 1993-07-19 1997-10-01 Angiotech Pharmaceuticals, Inc. Compositions anti-angiogéniques et leurs procédés d'utilisation
US20050123605A1 (en) * 1993-07-19 2005-06-09 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20060121117A1 (en) * 1993-07-19 2006-06-08 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20060240113A1 (en) * 1993-07-19 2006-10-26 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US7820193B2 (en) 1993-07-19 2010-10-26 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US20070003629A1 (en) * 1993-07-19 2007-01-04 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
EP2226085A1 (fr) 1993-07-19 2010-09-08 Angiotech Pharmaceuticals, Inc. Compositions anti-angiogéniques et leurs procédés d'utilisation
US20050208137A1 (en) * 1993-07-19 2005-09-22 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
US6433189B2 (en) 1993-07-20 2002-08-13 Florida State University Tricyclic and tetracyclic taxane intermediates
US5405972A (en) * 1993-07-20 1995-04-11 Florida State University Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes
US6861537B2 (en) 1993-07-20 2005-03-01 Florida State University Tricyclic and tetracyclic taxane intermediates
US5760252A (en) * 1993-07-20 1998-06-02 Florida State University Synthetic process for the preparation of tricyclic and tetracyclic taxanes
US5618952A (en) * 1993-07-20 1997-04-08 Florida State University Synthetic process for the preparation of tricyclic and tetracyclic taxanes
US6005120A (en) * 1993-07-20 1999-12-21 Florida State University Tricyclic and tetracyclic taxanes
US5637732A (en) * 1993-07-20 1997-06-10 Florida State University Tricyclic and tetracyclic taxanes
AU694941B2 (en) * 1993-08-17 1998-08-06 Bristol-Myers Squibb Company Phosphonooxymethyl ethers of taxane derivatives
US5622986A (en) * 1993-10-20 1997-04-22 Enzon, Inc. 2'-and/or 7-substituted taxanes
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US6441026B1 (en) 1993-11-08 2002-08-27 Aventis Pharma S.A. Antitumor compositions containing taxane derivatives
US6022985A (en) * 1994-07-08 2000-02-08 Rhone-Poulenc Rorer S.A. Process for the preparation of 4-acetoxy-2α-benzoyloxy-5β, 20-epoxy-1, 7β-10β-trihydroxy-9-oxo-tax-11-en-13α-yl(2R,3S)-3-tert-b utoxy-carbonYlamino-2-hydroxy-3-phenylpropionate trihydrate
US6201140B1 (en) * 1994-07-28 2001-03-13 Bristol-Myers Squibb Company 7-0-ethers of taxane derivatives
EP0694539A1 (fr) 1994-07-28 1996-01-31 Bristol-Myers Squibb Company 7-0-éthers de dérivés de taxane
US6458976B1 (en) 1994-10-28 2002-10-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents, pharmaceutical compositions, and treatment methods
US6100411A (en) * 1994-10-28 2000-08-08 The Research Foundation Of State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6096909A (en) * 1994-10-28 2000-08-01 The Research Foundation Of State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6835746B2 (en) 1994-10-28 2004-12-28 The Research Foundation Of State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6500858B2 (en) 1994-10-28 2002-12-31 The Research Foundation Of The State University Of New York Taxoid anti-tumor agents and pharmaceutical compositions thereof
US6372780B2 (en) 1995-03-27 2002-04-16 Aventis Pharma S.A. Methods of treating cell lines expressing multidrug resistance P-glycoprotein
US6331635B1 (en) 1995-03-27 2001-12-18 Aventis Pharma S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US5847170A (en) * 1995-03-27 1998-12-08 Rhone-Poulenc Rorer, S.A. Taxoids, their preparation and pharmaceutical compositions containing them
US6387946B1 (en) 1995-03-27 2002-05-14 Aventis Pharma S.A. Methods for treating pathological conditions of abnormal cell proliferation
US5760251A (en) * 1995-08-11 1998-06-02 Sepracor, Inc. Taxol process and compounds
US5654448A (en) * 1995-10-02 1997-08-05 Xechem International, Inc. Isolation and purification of paclitaxel from organic matter containing paclitaxel, cephalomannine and other related taxanes
US5840748A (en) * 1995-10-02 1998-11-24 Xechem International, Inc. Dihalocephalomannine and methods of use therefor
US5840930A (en) * 1995-10-02 1998-11-24 Xechem International, Inc. Method for production of 2", 3" dihalocephalomannine
US6177456B1 (en) 1995-10-02 2001-01-23 Xechem International, Inc. Monohalocephalomannines having anticancer and antileukemic activity and method of preparation therefor
US5854278A (en) * 1995-12-13 1998-12-29 Xechem International, Inc. Preparation of chlorinated paclitaxel analogues and use thereof as antitumor agents
US5807888A (en) * 1995-12-13 1998-09-15 Xechem International, Inc. Preparation of brominated paclitaxel analogues and their use as effective antitumor agents
WO1997032578A1 (fr) * 1996-03-04 1997-09-12 The Research Foundation Of State University Of New York Agent antitumoraux taxoides et compositions pharmaceutiques contenant de tels agents
WO1997042181A1 (fr) * 1996-05-06 1997-11-13 Florida State University 1-deoxy baccatine iii, 1-deoxy taxol, analogues de 1-deoxy taxol, et procedes de fabrication correspondants
US20040029976A1 (en) * 1996-05-06 2004-02-12 Florida State University 1- Deoxy baccatin III, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof
US6620950B2 (en) 1996-05-06 2003-09-16 Florida State University Method for the preparation of 1-deoxy baccatin III, 1-deoxy taxol and 1-deoxy taxol analogs
US7019150B2 (en) 1996-05-06 2006-03-28 Florida State University 1-deoxy taxol analogs
AU724499B2 (en) * 1996-05-06 2000-09-21 Florida State University 1-deoxy baccatin III, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof
US6545168B1 (en) 1996-05-06 2003-04-08 Florida State University 1-deoxy baccatin III, 1-deoxy taxol and 1-deoxy taxol analogs and method for the preparation thereof
US5635531A (en) * 1996-07-08 1997-06-03 Bristol-Myers Squibb Company 3'-aminocarbonyloxy paclitaxels
AU731651B2 (en) * 1996-07-11 2001-04-05 Napro Biotherapeutics, Inc. Method for acylating 10-deacetylbaccatin III selectively at the C-10 position
US5750736A (en) * 1996-07-11 1998-05-12 Napro Biotherapeutics, Inc. Method for acylating 10-deacetylbaccatin III selectively at the c-10 position
WO1998002427A1 (fr) * 1996-07-11 1998-01-22 Napro Biotherapeutics, Inc. Procede d'acylation selective de 10-desacetylbaccatine iii en position c-10
CN1096453C (zh) * 1996-07-11 2002-12-18 拿坡罗生物治疗股份有限公司 使10－去乙酰基浆果赤霉素iii在c－10位选择性酰化的方法
CN1097586C (zh) * 1996-09-25 2003-01-01 拿坡罗生物治疗股份有限公司 合成红豆杉醇的方法
US5973170A (en) * 1996-09-25 1999-10-26 Napro Biotherapuetics, Inc. C-7 metal alkoxides of baccatin III
US6133462A (en) * 1996-09-25 2000-10-17 Napro Biotherapeutics, Inc. C-7 CBZ baccatin III and production method therefor
US5912264A (en) * 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
US6017935A (en) * 1997-04-24 2000-01-25 Bristol-Myers Squibb Company 7-sulfur substituted paclitaxels
EP1170293A3 (fr) * 1997-08-18 2002-04-03 Florida State University Procédé de dérivatisation selective de taxanes
SG97986A1 (en) * 1997-08-18 2003-08-20 Univ Florida State Process for selective derivatization of taxanes
EP0956284A4 (fr) * 1997-08-18 2001-12-05 Univ Florida State Procede de derivatisation selective de taxanes
EP1170292A2 (fr) * 1997-08-18 2002-01-09 Florida State University Procédé de dérivatisation selective de taxanes
EP1170293A2 (fr) * 1997-08-18 2002-01-09 Florida State University Procédé de dérivatisation selective de taxanes
EP1170292A3 (fr) * 1997-08-18 2002-04-03 Florida State University Procédé de dérivatisation selective de taxanes
US6706896B1 (en) 1997-08-18 2004-03-16 Florida State University Process for selective derivatization of taxanes
US5914411A (en) * 1998-01-21 1999-06-22 Napro Biotherapeutics, Inc. Alternate method for acylating 10-deacetylbaccatin III selectively at the C-10 position
US6156789A (en) * 1998-03-17 2000-12-05 Rhone-Poulenc Rorer S.A. Method for treating abnormal cell proliferation in the brain
US6448417B1 (en) 1998-05-01 2002-09-10 Napro Biotherapeutics, Inc. Methods and useful intermediates for paclitaxel synthesis from C-7, C-10 di-cbz 10-deacetylbaccatin III
US6066749A (en) * 1998-05-01 2000-05-23 Napro Biotherapeutics, Inc. Method for conversion of C-2'-O-protected-10-hydroxy taxol to c-2'-O-protected taxol:useful intermediates in paclitaxel synthesis
US6048990A (en) * 1998-05-01 2000-04-11 Napro Biotherapeutics, Inc. Method for selective acylation of C-2'-O-protected-10-hydroxy-taxol at the C-10 position
US6025516A (en) * 1998-10-14 2000-02-15 Chiragene, Inc. Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes
WO2000049006A1 (fr) * 1999-02-19 2000-08-24 Napro Biotherapeutics, Inc. C-7 alcoxydes metalliques de baccatin iii
US6136999A (en) * 1999-06-21 2000-10-24 Napro Biotherapeutics, Inc. C-2 hydroxyl protected-n-acyl (2R,3S)-3-phenylisoserine substituted phenyl activated esters and method for production thereof
US6143902A (en) * 1999-06-21 2000-11-07 Napro Biotherapeutics, Inc. C-2 hydroxyl protected-N-acyl (2R,3S)-3-phenylisoserine N-imido activated esters and method for production thereof
EP2266607A2 (fr) 1999-10-01 2010-12-29 Immunogen, Inc. Des immunoconjugués pour le traitement des cancers.
EP2289549A2 (fr) 1999-10-01 2011-03-02 Immunogen, Inc. Des immunoconjugués pour le traitement des cancers.
US7067305B2 (en) 1999-10-18 2006-06-27 Fsu Research Foundation, Inc. Enzymatic process for the resolution for enantiomeric mixtures of β-lactams
US20030190743A1 (en) * 1999-10-18 2003-10-09 Fsu Research Foundation, Inc. Enzymatic process for the resolution of enantiomeric mixtures of beta-lactams
US6548293B1 (en) 1999-10-18 2003-04-15 Fsu Research Foundation, Inc. Enzymatic process for the resolution of enantiomeric mixtures of β-lactams
US7063977B2 (en) 2001-08-21 2006-06-20 Bristol-Myers Squibb Company Enzymatic resolution of t-butyl taxane derivatives
US20030069415A1 (en) * 2001-08-21 2003-04-10 Patel Ramesh N. Enzymatic resolution of t-butyl taxane derivatives
US6858644B2 (en) 2001-11-30 2005-02-22 Bristol-Myers Squibb Co. Paclitaxel solvates
US20030144344A1 (en) * 2001-11-30 2003-07-31 Benigni Daniel A. Paclitaxel solvates
US20040142705A1 (en) * 2002-01-30 2004-07-22 Microsoft Corporation Proximity sensor with adaptive threshold
US20040132991A1 (en) * 2002-10-09 2004-07-08 Phytogen Life Sciences Inc. Novel taxanes and methods related to use and preparation thereof
US20050054863A1 (en) * 2003-08-07 2005-03-10 Gibson Frank S. Process for preparing 4-alkyl- or 4-aryl-oxycarbonyl paclitaxel analogs and novel intermediates
US7030253B2 (en) 2003-08-07 2006-04-18 Bristol-Myers Squibb Company Process for preparing 4-alkyl- or 4-aryl-oxycarbonyl paclitaxel analogs and novel intermediates
US7202370B2 (en) 2003-10-27 2007-04-10 Conor Medsystems, Inc. Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III
US20050101789A1 (en) * 2003-10-27 2005-05-12 Phytogen Life Sciences Inc. Semi-synthesis of taxane intermediates from 9-dihydro-13-acetylbaccatin III
US20070027207A1 (en) * 2004-06-04 2007-02-01 Ragina Naidu Semi-synthesis of taxane intermediates and their conversion to paclitaxel and docetaxel
US20070027330A1 (en) * 2004-06-25 2007-02-01 Ragina Naidu One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel
US20050288520A1 (en) * 2004-06-25 2005-12-29 Phytogen Life Sciences Inc. One pot synthesis of taxane derivatives and their conversion to paclitaxel and docetaxel
US20060236917A1 (en) * 2005-04-21 2006-10-26 Atsushi Denda Method of forming conductive film and method of manufacturing electronic apparatus
US20090170928A1 (en) * 2005-04-28 2009-07-02 Bruno Ferdinando F Synthesis of oligo/poly(catechins) and methods of use
US8143308B2 (en) 2005-04-28 2012-03-27 University Of Massachusetts Lowell Synthesis of oligo/poly(catechins) and methods of use
US7662980B2 (en) 2006-10-20 2010-02-16 Scinopharm Singapore Pte Ltd. Crystalline forms of docetaxel and process for preparation thereof
US20090275762A1 (en) * 2006-10-20 2009-11-05 Yuan-Xiu Liao Crystalline Forms of Docetaxel and process for Preparation Thereof
US20080108693A1 (en) * 2006-10-20 2008-05-08 Scinopharm Singapore Pte Ltd. Crystalline forms of docetaxel and process for preparation thereof
US8357811B2 (en) 2006-10-20 2013-01-22 ScnioPharm Singapore PTE Ltd. Crystalline forms of docetaxel and process for preparation thereof
US20090292131A1 (en) * 2008-05-07 2009-11-26 Ladislav Cvak Processes for preparation of taxanes and intermediates thereof

Also Published As

Publication number Publication date
AU2688892A (en) 1993-04-27
HU225914B1 (en) 2007-12-28
PT100884A (pt) 1993-11-30
RU2098413C1 (ru) 1997-12-10
NZ244458A (en) 1994-06-27
CZ289299B6 (cs) 2001-12-12
EP0605638B1 (fr) 1999-09-01
HU9400831D0 (en) 1994-06-28
IL103192A0 (en) 1993-02-21
CA2098568A1 (fr) 1993-03-24
IL103192A (en) 1997-06-10
FI109796B (fi) 2002-10-15
DE69229916T2 (de) 2000-02-17
WO1993006094A1 (fr) 1993-04-01
CN1075718A (zh) 1993-09-01
MY128481A (en) 2007-02-28
PT100884B (pt) 1999-07-30
FI941323A (fi) 1994-03-22
EP0605638A4 (en) 1994-08-24
CN1058714C (zh) 2000-11-22
CZ66294A3 (en) 1994-12-15
AU643911B2 (en) 1993-11-25
TW368502B (en) 1999-09-01
NO941020D0 (no) 1994-03-22
ATE184004T1 (de) 1999-09-15
UA41287C2 (uk) 2001-09-17
JP3320416B2 (ja) 2002-09-03
ES2137951T3 (es) 2000-01-01
FI941323A0 (fi) 1994-03-22
PH30213A (en) 1997-02-05
HUT66398A (en) 1994-11-28
MX9205370A (es) 1993-03-31
DE69229916D1 (de) 1999-10-07
JPH07502982A (ja) 1995-03-30
DK0605638T3 (da) 2000-02-28
EP0605638A1 (fr) 1994-07-13
NO305120B1 (no) 1999-04-06
CA2098568C (fr) 1997-06-03
NO941020L (no) 1994-05-20

Similar Documents

Publication Publication Date Title
US5229526A (en) Metal alkoxides
US5274124A (en) Metal alkoxides
US5723634A (en) Metal alkoxide compounds
US5254703A (en) Semi-synthesis of taxane derivatives using metal alkoxides and oxazinones
EP0884314B1 (fr) Alkoxydes de métaux
US6124481A (en) Ammonium alkoxides
EP0668762B1 (fr) Taxanes a substitution isobutenyle et compositions pharmaceutiques les contenant
US7074945B2 (en) Metal alkoxide taxane derivatives
AU647971C (en) Preparation of isoserine ester and taxane

Legal Events

Date Code Title Description
AS Assignment

Owner name: FLORIDA STATE UNIVERSITY, FLORIDA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:HOLTON, ROBERT A.;REEL/FRAME:006144/0634

Effective date: 19920602

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
CC Certificate of correction
FEPP Fee payment procedure

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REFU Refund

Free format text: REFUND PROCESSED. MAINTENANCE FEE HAS ALREADY BEEN PAID (ORIGINAL EVENT CODE: R160); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE;ASSIGNOR:FLORIDA STATE UNIVERSITY;REEL/FRAME:020917/0318

Effective date: 19960521